Other names: BGP; BGPI; BGP1; CD66a; BGP HGNC (Hugo): CEACAM1 Location: 19q13.2 Local order: centromere
Description
The gene is composed of 9 exons spanning in a region of 23,140 bp (Localized from 47,724,479 to 47,703,298 from pter).
Transcription
Human CEACAM1 consists of 9 exons that can be alternatively spliced to generate 11 different isoforms. The gene contains 19 different introns, and the sequence is supported by 286 sequences from 262 cDNA clones. The transcripts differ by truncation of the N-terminus, truncation of the C-terminus, presence or absence of a cassette exon, common exons with different boundaries. Among various types of isoforms, the full-length nature of two alternative transcripts (NM_001024912.1, NM_001712.3) has been determined.
Pseudogene
Eleven pseudogenes of the CEA cell adhesion molecule subgroup are found in the cluster of the two subgroups of the CEA family (the CEA cell adhesion molecules and the pregnancy-specific glycoproteins which locate within a 1.2 Mb cluster on the long arm of chromosome 19).
In human, 11 different CEACAM1 splice variants have been reported. The domain structure of each protein isoform is illustrated as open box. N; N-terminal immunoglobulin variable-region-like (IgV-like) domain, A or B; subsets of constant-region-type-2-like (IgC2-like) domains, TM; transmembrane domain, C; cytoplasmic domain. Nomenclature number after CEACAM1 indicates the number of extracellular immunoglobulin-like domains, whereas the letter that follows this indicates the presence of either a long (L) or a short (S) cytoplasmic tail, a unique termini (C), or an Alu family repeat sequence present within the open reading frame (A). For example, CEACAM1 with four extracellular immunoglobulin-like domains and with a long cytoplasmic domain is called as CEACAM1-4L. The most common isoforms expressed by human immune cells are CEACAM1-4L, CEACAM1-3L, CEACAM1-4S and CEACAM1-3S.
Protein

Description
CEACAM1 is a single-pass type-1 glycoprotein which belongs within the Ig gene superfamily. It contains a 34 amino acid (aa) leader sequence, an extracellular domain which contains a N-terminal IgV-like domain and three of IgC2-like domains (382 aa), a transmembrane domain (43 aa), a cytoplasmic domain (67 aa) and two of the potential tyrosine phosphorylation sites. CEACAM1 is heavily Nglycosylated with more than 60% of the mass contributed by N-linked glycans.
Localisation
CEACAM1 isoforms with transmembrane domain are mostly cell-membrane anchored, whereas those without transmembrane domain are secreted. They are mostly expressed in cells of epithelial and endothelial, lymphoid and myeloid cells.
Function
CEACAM1 is capable of homophilic with CEACAM1 or heterophilic adhesion with CEA and CEACAM6. Isoforms of CEACAM1 with a long cytoplasmic domain generally transmit inhibitory signals, whereas isoforms with a short cytoplasmic domain indicate a regulated interaction with the cytoskeleton. CEACAM1 has been implicated in various types of intercellularadhesion and intracellular-signaling of cell survival, differentia-tion and growth in both normal and cancer cells as follows:
(1) CEACAM1 inhibits proliferation of both epithelial cells and T lymphocytes by a contact-mediated mechanism. In monocytes, CEACAM1 regulates phosphatidylinositol 3-kinase (PI3K) and Aktdependent survival signal and inhibits apoptosis. (2) CEACAM1 induces apoptosis of mature colonocytes and mammary epithelial cells, which is in part of a morphogenetic process in the formation of glandular lumen. (3) CEACAM1 has been demonstrated to stimulate cellular migration of blood vessel endothelial cells. (4) In granulocytes, CEACAM1 mediates the binding to endothelial E-selectin. (5) The involvement of CEACAM1 in carcinogenesis is complex. In some types of cancer cells such as colon cancer and hepatoma loss or reduced expression of CEACAM1 is frequently observed, thereby it has been regarded as a tumor suppressor. However, in other types, for example, thyroid cancer and gastric cancer, CEACAM1 is up-regulated. (6) CEACAM1 exerts angiogenic properties and is a major effecter of VEGF in the early vascular formation.
Since CEACAM1 is mainly expressed in tumor microvessels but not in large blood vessels, it may be a target for the therapy of tumor angio-genesis. (7) Neisseria gonorrhea triggers expression of CEACAM1 on primary endothelial cells by activating the immediate early response trans-cription factor NFkappaB. Neisseria gonorrhoeae colony opacity-associated (Opa) proteins bind to human CEACAM on host cells including T lymphocytes, and Opa binding to CEACAM1 suppresses the activation of CD4+ T cells in response to a variety of stimuli. (8) CEACAM1 regulates insulin clearance in the liver.
Homology
CEACAM1 is the human homolog of a cell adhesion molecule (CAM) of the rat designated Cell-CAM. Rattus norvegicus: 70.74 (n), 56.12(a) (Percentage Identity). Mus musculus: 72.3 (n), 58.25 (a).
Implicated in
Colon cancer
Note CEACAM1 mRNA was demonstrated to be downregulated to < or = 0.4 in 80% of 21 colorectal carcinoma tissue specimens as compared with the respective adjacent normal mucosa (Neumaier et al., 1993) . CEACAM1 was reported to be associa-ted with pp60c-src, suggesting that down-regulation of CEACAM1 in about 80% of colorectal carcino-mas may contribute to a dysfunction of pp60c-src in colorectal cancer (Brummer et al., 1995) .
Hepatocellular carcinoma
Note CEACAM1 was reported to be diffusely expressed in 113 of 139 hepatomas. Loss of CEACAM1 expression was closely associated with large tumor size, multiplicity of the tumor, portal vein invasion, and satellite nodules and affected survival adversely, according to univariate (P < 0.0001) and multivariate analyses (relative risk, 5.737; P < 0.001) (Cruz et al., 2005) . In rat hepatoma cells 1682A, restoration of CEACAM1-4L expression was demonstrated to completely suppress the tumor formation (Laurie et al., 2005) . In human hepatoma cell lines (HLF, PLC/PRF/5, HepG2 and KYN-2), CEACAM1 protein was demonstrated to only express in HepG2, which shows a strong property for enhanced anchorageindependent growth. It was reported that CEACAM1 acts as a tumor suppressor when the cells are cultured in anchorage-dependent growth conditions. In contrast, in anchorage-independent growth conditions, CEACAM1 augments cell proliferation by potentiating the cell-cell attachment (Hokari et al., 2007) .
Breast cancer
Note CEACAM1 is down-regulated in around 30% of breast cancers. CEACAM1 is reported to suppress the tumorigenicity of breast cancer cells via its cytoplasmic domain but not the extracellular domain (Luo et al., 1997) . CEACAM1 is demonstrated to be consistently expressed in normal tissue and benign lesions of mammary gland, whereas it disappears with the development of the malignant phenotype in both noninvasive and invasive carcinoma (Riethdorf et al., 1997) . CEACAM1 is reported to be expressed at high levels in cribiform ductal carcinoma in situ (DCIS). Although most invasive ductal carcinomas express CEACAM1 weakly, tumours with minimal lumena formation show cytoplasmic CEACAM1 expression (Kirshner et al., 2004) .
Prostate cancer
Note CEACAM1 is reported to be regulated by androgen and might act as a growth repressor during differentiation of the prostatic epithelium. Forced expression of CEACAM1 results in the significan-tly lower growth rates of human prostatic cancer cell line PC-3 (Hsieh et al., 1995) .
Bladder cancer
Note CEACAM1 is expressed in umbrella cells of bladder urothelium, but is down-regulated in superficial bladder cancer. CEACAM1 silencing in bladder cancer cell lines 486p and RT4 using the small interfering RNA technique leads to a significant up-regulation of vascular endothelial growth factor (VEGF)-C and VEGF-D, suggesting that the epithelial downregulation of CEACAM1 induces angiogenesis via increased expression of VEGF-C and VEGF-D (Oliveira-Ferrer et al., 2004) .
Melanoma
Note A total of 28 of 40 patients with CEACAM1-positive primary melanomas developed metastatic disease, compared with only six of 60 patients with CEACAM1-negative melanomas. the strongest CEACAM1 expression was observed at the invading front. Kaplan-Meier analysis revealed a highly significant association between CEACAM1 expression and metastasis (P <.0001) (Thies et al., 2002) .
Renal cell carcinoma
Note
In normal kidney, CEACAM1 was found in epithelial cells of proximal tubules and in endothel-ial cells. In contrast, tumour cells of 30 clear cell, three chromophobic, and two chromophilic RCCs were completely devoid of CEACAM1. Renal adenomas also lacked CEACAM1 expression. Similarly, RCC cell lines CaKi1, CaKi2, A498, and RCC26 exhibited no or low-level CEACAM1 expression. However, CEACAM1 expression was transiently induced in A498 cells upon contact with allogeneic CD8+ T cells, mediated at least in part by interferon-gamma. Furthermore, the majority of tumour-infiltrating T and NK cells expressed CEACAM1 upon stimulation. Thus, transient expression of the tumour suppressor CEACAM1 by tumour cells and subsequent homophilic interaction with CEACAM1 on tumourinfiltrating lympho-cytes could represent a novel immune escape mechanism in RCC (Kammerer et al., 2004) .
To be noted
Note
The role of CEACAM1 in cancer may be different among different types of cancer. CEACAM1 is downregulated in colon carcinomas, hepatocellular carcinomas, a proportion of breast cancers. In contrast, in prostate cancer and bladder cancer, CEACAM1 is down-regulated in the cancer cells, whereas overexpressed in blood microvessels and lymphatic capillaries and in the vicinity of the tumor. In thyroid cancer, gastric cancer and metastasing malignant melanomas, CEACAM1 is increased. 
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